Please provide your email address to receive an email when new articles are posted on . Incidence of 30-day rebleeding was 7.1% in the vonoprazan group and 10.4% in the proton pump inhibitor group.
Objective and design: The use of proton pump inhibitors in acid-related diseases such as peptic ulcer or erosive reflux oesophagitis is well established. The aim of the current nationwide, multicentre ...
The REVISE trial previously demonstrated that the IV proton pump inhibitor pantoprazole reduced clinically important upper gastrointestinal bleeding without a mortality risk in critically ill adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results